北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2025 年第一次临时股东大会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 R 霍UT = 3 Pr A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI`AN 致:北京万东医疗科技股份有限公司 g n f 北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2025 年第一次临时股东大会的法律意见书 嘉源(2025)-04-410 北京市嘉源律师事务所(以下简称"本所")接受北京万东医疗科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《北京万东医疗科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司 2025年第一次临时股东大会(以下简称"本次 股东大会"）进行见证,并依 ...

北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2025 年第一次临时股东大会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 R 霍UT = 3 Pr A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI`AN 致:北京万东医疗科技股份有限公司 北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2025 年第一次临时股东大会的法律意见书 嘉源(2025)-04-410 北京市嘉源律师事务所(以下简称"本所")接受北京万东医疗科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《北京万东医疗科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司 2025年第一次临时股东大会(以下简称"本次 股东大会"）进行见证,并依法出具本法律 ...

证券代码：600055 证券简称：万东医疗 公告编号：2025-029 北京万东医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 6 月 9 日 (二) 股东大会召开的地点：公司本部（北京市朝阳区酒仙桥东路 9 号院 3 号楼） 1、 公司在任董事7人，出席7人； 2、 公司在任监事3人，出席3人； (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份 情况： | 1、出席会议的股东和代理人人数 | 202 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 330,324,605 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 46.9837 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情 况等。 会议由公司董事长马赤兵先生主持，采取现场 ...

证券代码：600055 证券简称：万东医疗 编号：临 2025-031 北京万东医疗科技股份有限公司 第十届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北京万东医疗科技股份有限公司（以下简称"公司"）第十届董事会 第九次会议于 2025 年 6 月 9 日以通讯表决方式召开。本次会议的会议通知 及相关资料于 2025 年 6 月 5 日以电子邮件的方式向全体董事发出。会议应 到董事 8 人，实到 8 人，公司高管人员列席会议。本次会议的召开符合《公 司法》和《公司章程》的规定，所作决议合法有效。 依据《公司章程》规定，会议由董事长马赤兵先生主持，形成如下决 议： 一、审议通过《关于调整第十届董事会部分专门委员会委员的议案》。 为完善公司治理结构，保证董事会专门委员会能够顺利高效开展工作, 充分发挥其职能，公司对第十届董事会战略委员会、薪酬与考核委员会的 委员进行调整，任期自董事会审议通过之日起至第十届董事会任期届满。 本次调整后，马赤兵先生为董事会战略委员会成员、薪酬与考核委员 会成员，并担任董 ...

证券代码：600055 证券简称：万东医疗 编号：临 2025-031 本次调整后，马赤兵先生为董事会战略委员会成员、薪酬与考核委员 会成员，并担任董事会战略委员会召集人。 公司第十届董事会战略委员会、薪酬与考核委员会组成情况如下： 董事会战略委员会：马赤兵先生、宋金松先生、钟铮女士、刘啸先生， 马赤兵先生为召集人。 董事会薪酬与考核委员会：赵俊先生（独立董事）、孙岩女士（独立董 事）、马赤兵先生，赵俊先生为召集人。 北京万东医疗科技股份有限公司 第十届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北京万东医疗科技股份有限公司（以下简称"公司"）第十届董事会 第九次会议于 2025 年 6 月 9 日以通讯表决方式召开。本次会议的会议通知 及相关资料于 2025 年 6 月 5 日以电子邮件的方式向全体董事发出。会议应 到董事 8 人，实到 8 人，公司高管人员列席会议。本次会议的召开符合《公 司法》和《公司章程》的规定，所作决议合法有效。 依据《公司章程》规定，会议由董事长马赤兵先生主持，形成如 ...

Investment Rating - The report does not explicitly state an investment rating for the XR equipment industry Core Insights - The XR equipment industry is experiencing significant growth driven by technological advancements, policy support for domestic alternatives, and increasing demand in the healthcare sector. The market is expected to expand due to factors such as the aging population, rising cardiovascular disease rates, and the implementation of new healthcare policies [4][20][32]. Summary by Sections Industry Definition - XR equipment utilizes X-rays to obtain internal imaging information based on the differential absorption and attenuation of X-rays by various tissues. It is widely used in medical diagnostics, security, and industrial applications, with a focus on medical health in this report [5]. Industry Characteristics - The XR equipment industry is characterized by: - **Technology-Intensive and Innovation-Driven**: The industry relies heavily on technological innovation, particularly in digitalization, AI integration, and low-dose imaging technologies [10]. - **Policy-Driven and Accelerated Domestic Replacement**: Government policies are significantly influencing the market, promoting the use of domestic medical devices [12]. - **Diverse Application Scenarios and Market Segmentation**: XR equipment applications extend beyond traditional medical diagnostics to include industrial inspection and security [13]. Development History - The development of XR equipment in China has gone through three phases: initial reliance on foreign technology, a period of domestic growth supported by policy, and a current phase of technological breakthroughs and international market expansion [14]. Industry Chain Analysis - The XR equipment industry chain includes: - **Upstream**: Comprising core component manufacturing such as chips and sensors, with low domestic production rates [17]. - **Midstream**: Focused on the assembly of devices and content development, with a notable shift towards domestic production [19]. - **Downstream**: Concentrated on application promotion and sales across various sectors, with hospitals being the primary customers [29]. Market Size and Growth - The XR equipment market size is projected to grow from 11.2 billion RMB in 2019 to 14.51 billion RMB in 2024, with a compound annual growth rate (CAGR) of 5.31% [33]. The market is expected to continue expanding due to increasing healthcare demands and supportive policies [36]. Policy Overview - Key policies influencing the XR equipment industry include: - **Equipment Update Policies**: Encouraging medical institutions to upgrade their imaging equipment [41]. - **Support for Domestic Production**: Policies aimed at promoting the use of domestic medical devices [42]. Competitive Landscape - The XR equipment market is dominated by major international players like Siemens, Philips, and GE in the high-end segment, while domestic companies such as United Imaging, Mindray, and Wandong Medical are gaining traction in the mid to low-end markets [44]. The competition is characterized by a clear segmentation based on hospital tiers and equipment preferences [45]. Future Outlook - The XR equipment industry is poised for growth driven by technological advancements, policy support for domestic manufacturers, and increasing healthcare needs, particularly in the context of an aging population and rising chronic disease prevalence [40][46].

Investment Rating - The report indicates a positive investment outlook for the XR equipment industry, driven by technological advancements and policy support for domestic manufacturers [4][11][41]. Core Insights - XR devices are essential in medical diagnostics, particularly for cardiovascular diseases, and are expected to evolve towards smart, low-dose, and high-precision technologies [4][5][9]. - The market for XR devices is projected to grow significantly due to increasing demand from grassroots medical institutions and the aging population [4][31][40]. - Domestic manufacturers are gaining market share due to favorable policies promoting local production and innovation [11][19][45]. Summary by Sections Industry Overview - XR devices are widely used in medical, security, and industrial fields, with a strong emphasis on medical applications for diagnosing various diseases [5][9]. - The industry is characterized by high technological intensity and innovation, with a focus on digitalization and AI integration [9][19]. Market Dynamics - The XR equipment market is expected to grow from 112 billion RMB in 2019 to 145.1 billion RMB by 2024, with a compound annual growth rate (CAGR) of 5.31% [33]. - The demand for XR devices is driven by policies that enhance the capabilities of grassroots medical services and the increasing prevalence of cardiovascular diseases [37][40]. Competitive Landscape - The market is dominated by international brands like Siemens, Philips, and GE in the high-end segment, while domestic brands such as United Imaging and Wandong Medical are gaining traction in the mid to low-end markets [45][46]. - The competitive dynamics are influenced by the differing needs of hospitals at various levels, with tertiary hospitals favoring high-end imported devices and secondary hospitals leaning towards cost-effective domestic options [46]. Policy Impact - Government policies are significantly influencing the XR equipment market, with initiatives aimed at promoting domestic production and upgrading medical equipment in grassroots healthcare settings [11][41][42]. - The "14th Five-Year Plan" for medical equipment development aims to enhance the technological capabilities and quality of medical devices, further supporting the growth of the XR equipment industry [41][42].

万东医疗 2025 年第一次临时股东大会会议资料 北京万东医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 6 月 万东医疗 2025 年第一次临时股东大会会议资料 交易系统投票平台投票时间：2025 年 6 月 9 日交易时间段。 互联网投票平台投票时间：2025 年 6 月 9 日 9:15-15:00。 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式。 股东大会召集人：公司董事会 现场会议地点：北京市朝阳区酒仙桥东路 9 号院 3 号楼。 参加会议人员：2025 年 6 月 3 日下午收市后，在中国证券登记结算有 限公司上海分公司登记在册的本公司股东及股东代表；公司董事、监事及 高级管理人员；律师。 会议登记时间：2025 年 6 月 5 日上午 9：00-11：30，下午 13：00－17： 00。 会议议程： 一、主持人宣布股东到会情况 北京万东医疗科技股份有限公司 2025 年第一次临时股东大会会议议程 现场会议时间：2025 年 6 月 9 日下午 13:00 时。 二、审议会议议案、按审议事项的顺序逐项投票表决 议案 1：关于取消监事会并修订 ...

Core Viewpoint - Beijing Wandong Medical Technology Co., Ltd. has completed the registration of its 2025 stock option incentive plan, granting a total of 9.6 million stock options to 85 individuals, with the registration completed on May 30, 2025 [2][11]. Summary by Sections Stock Option Grant Details - The stock option grant date is May 21, 2025, with a total of 9.6 million options granted to 85 individuals at an exercise price of 15.05 yuan per option [6][12]. - The incentive plan is valid for a maximum of 60 months from the grant date, with waiting periods of 12, 24, and 36 months for different portions of the options [7]. Approval Process - The plan underwent several approval steps, including meetings of the board and supervisory committee, public announcements, and shareholder meetings, culminating in the approval at the annual general meeting on April 16, 2025 [3][4]. - The board authorized the handling of the incentive plan's related matters, and the supervisory committee verified the list of incentive recipients [4][11]. Performance Assessment Criteria - The performance assessment for the stock options is based on the company's revenue growth and R&D investment rates over the fiscal years 2025 to 2027, with specific targets set against the 2024 revenue as a baseline [9][10]. - Individual performance assessments will also be conducted, with a grading system from S to D determining the proportion of options that can be exercised [10]. Financial Impact - The company will calculate the fair value of the stock options using the Black-Scholes model, and the expenses related to the stock options will be recognized in accordance with accounting standards [12][13].

Core Viewpoint - Beijing Wandong Medical Technology Co., Ltd. has completed the registration of its 2025 stock option incentive plan, granting a total of 9.6 million stock options to 85 individuals, with the registration completed on May 30, 2025 [1][2][9] Group 1: Stock Option Plan Details - The stock option plan has a maximum validity period of 60 months from the date of the first grant [5] - The waiting periods for the stock options are set at 12, 24, and 36 months, with specific percentages of options available for exercise at each stage [5][6] - The performance assessment for the stock options will be based on the company's revenue growth and R&D investment rates over the fiscal years 2025 to 2027 [6][7] Group 2: Performance Assessment Criteria - The performance targets for the first, second, and third exercise periods are linked to the company's revenue, with specific thresholds set at 85% of the previous year's revenue [7][8] - Individual performance assessments will also influence the exercise of stock options, categorized into five levels (S, A, B, C, D) [8] Group 3: Financial Impact - The company will use the Black-Scholes model to calculate the fair value of the stock options, and adjustments will be made based on the number of options expected to be exercised and performance metrics [9]